Announced
Completed
Financials
Tags
biotechnology company
Biotechnology
Private
Private Equity
Friendly
United States
Acquisition
Domestic
Majority
Single Bidder
Completed
Synopsis
Thermo Fisher Scientific, a supplier of scientific instrumentation, completed the acquisition of CorEvitas, a provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity, an investment firm, for $913m. “We are very excited to welcome our new CorEvitas colleagues to Thermo Fisher. CorEvitas expands our clinical research business with highly complementary real-world evidence solutions, which is an increasingly important area and will help to enhance decision-making as well as the time and cost of drug development. We are excited by the opportunity to further accelerate innovation and advance productivity for our pharma and biotech customers in their work to deliver new medicines and therapeutics to benefit patients,” Marc N. Casper, Thermo Fisher Chairman, President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.